Raymond James Downgrades AMAG Pharmaceuticals (AMAG) to Underperform

Leerink Partners Downgrades AMAG Pharmaceuticals (AMAG) to Market Perform

Leerink Partners downgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Outperform to Market Perform with a price target of $25.00 (from $39.00).

For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.

Shares of AMAG Pharmaceuticals closed at $23.00 yesterday.

AMAG Pharma (AMAG), Palatin (PTN) Enter Pact for NA Rights to Rekyndatm

AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) together with Palatin Technologies, Inc. (NYSE PTN) today announced they have entered into an agreement for exclusive North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, that has successfully completed two Phase 3 trials. The anticipated filing date in the U.S. for a new drug application (NDA) for Rekynda is in early 2018, with an anticipated approval and launch by early 2019.

AMAG is excited to expand its womens health portfolio with a... More

AMAG Pharma (AMAG) Offers Q4 and FY17 Guidance

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today provided a business update, including announcing preliminary unaudited fourth quarter and annual 2016 financial results, 2017 financial guidance, and an update on its Makena® subcutaneous auto-injector program. In a separate release, the company also announced a licensing transaction for RekyndaTM (bremelanotide). The company will present further details at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 10, 2017 at 11:30 a.m. PT (2:30 p.m. ET). A live audio webcast of the presentation and the following breakout session will be accessible through the Investors section of... More